Our New Business Focus

Until recently, we were focused on the production and distribution of pharmaceutical products through our subsidiaries located in the People’s Republic of China.  We have recently refocused our core business strategy and market focus to the international commercialization of Onko-Sure™  and Elleuxe products.  On September 18, 2009, we changed our name from “AMDL, Inc.” to “Radient Pharmaceuticals Corporation.” We believe Radient Pharmaceuticals as a brand name has considerable market appeal and reflects our new corporate direction and branding statements.

We are now actively engaged in the research, development, manufacturing, sales and marketing of in vitro diagnostic (IVD) and high‐end skin care products. We have  a focused business strategy for the international commercialization and next generation product development for both of these products.  All of these business units focus on the development, manufacturing, distribution and sales of high-quality medical diagnostic products, generic pharmaceuticals, nutritional supplements, and cosmetics in the United States, Canada, China, Chile, Europe, India, Korea, Taiwan, Vietnam and other markets throughout the world.
We currently anticipate generating approximately $1.1 million in aggregate sales in 2009 from our Onko-Sure™  IVD cancer diagnostic test kits and our Elleuxe brand of skin care products. These two business segments are anticipated to be our largest revenue producing  products in the near future. We believe that  revenues from these products will significantly increase in 2010 due to the creation of regional distribution agreements that are anticipated to move the IVD cancer diagnostic test kits and the Elleuxe brand of skin care products into broad commercial channels in markets throughout the world. Currently, our business plan and budget estimates that sales from our Onko-Sure™  IVD cancer diagnostic test kits and our Elleuxe skin care products will grow to approximately $20 million in 2010. However, the success of our distribution strategy for these products in 2010 is dependent upon a number of factors including our obtaining adequate financing before the end of 2009.  We will need to obtain  approximately  $3,000,000 in additional financing during the 4th quarter of 2009, in order to execute our distribution plan for 2010.  If we are unable to raise sufficient funds, our distribution strategy may not be able to be implemented at the rate we anticipate, which will have a material adverse effect on our anticipated 2010 revenues.